Stay updated with breaking news from Pharma daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 11,270,000 shares, an increase of 39.5% from the May 15th total of 8,080,000 shares. Based on an average trading volume of 5,510,000 shares, the short-interest ratio is […] ....
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) was the target of a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 11,270,000 shares, an increase of 39.5% from the May 15th total of 8,080,000 shares. Based on an average daily trading volume, of 5,510,000 shares, […] ....
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $9.08 and last traded at $9.08, with a volume of 202576 shares changing hands. The stock had previously closed at $9.07. Analyst Ratings Changes Several brokerages recently issued reports […] ....
AIGH Capital Management LLC bought a new stake in CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) in the fourth quarter, HoldingsChannel reports. The fund bought 1,405,859 shares of the biopharmaceutical company’s stock, valued at approximately $8,449,000. CTI BioPharma accounts for approximately 2.8% of AIGH Capital Management LLC’s investment portfolio, making the stock its 14th biggest […] ....
StockNews.com initiated coverage on shares of CTI BioPharma (NASDAQ:CTIC – Get Rating) in a research report sent to investors on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other research analysts have also recently weighed in on CTIC. Lake Street Capital cut shares of CTI BioPharma from a buy […] ....